Login to Your Account



Other News To Note


Wednesday, September 21, 2011
SomaGenics Inc., of Santa Cruz, Calif., presented data on the efficacy of RNA interference (RNAi) therapeutics against hepatitis C virus (HCV) based on the company's sshRNA platform. SomaGenics' synthetic sshRNAs, formulated with lipid nanoparticles (LNP) from collaborator Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, demonstrated reduced circulating HCV load by more than two orders of magnitude.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription